Business
Faron Pharmaceuticals Presents Promising Phase 1/2 Data from BEXMAB Study at MDS 2025 Plenary Session
TURKU, FI / ACCESS Newswire / May 12, 2025 / Faron Pharmaceuticals (HEL:FARON)(LSE:FARN) - BEXMAB data highlights meaningful clinical benefit, with beneficial immunological and hematological impact in r/r MDS Encouraging survival; Median overall survival ...
About this update from Faron Pharmaceuticals Oy
[{"type":"text","content":"TURKU, FI / ACCESS Newswire / May 12, 2025 / Faron Pharmaceuticals (HEL:FARON)(LSE:FARN) - BEXMAB data highlights meaningful clinical benefit, with beneficial immunological and hematological impact in r/r MDS","length":208,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Encouraging survival; Median overall survival 13.4 months in 20 high and very high-risk r/r MDS patients treated with bexmarilimab + azacitidine; 4 patients successfully bridged to hematopoietic stem cell transplant","length":215,"tagName":"p"}]},{"val":[{"type":"text","content":"55% patients showed ≥50% reduction in bone marrow; 21% of transfusion-dependent patients became transfusion-independent","length":119,"tagName":"p"}]},{"val":[{"type":"text","content":"Faron will be hosting a virtual webinar to discuss the full analysis of r/r MDS as well as new frontline HR MDS patient data on Monday, 2 June 2025. To register for the event visit: BEXMAB Phase II study results","length":211,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":545,"olType":false},{"type":"text","content":"Turku, Finland - Faron Pharmaceuticals Ltd. (AIM: FARN, First North: FARON), a clinical-stage biopharmaceutical company advancing next-generation immunotherapies, presented updated data from its ongoing BEXMAB Phase 1/2 trial at plenary oral session at the 18th International Congress on Myelodysplastic Syndromes (MDS 2025) on May 10, 2025, in Rotterdam, Netherlands.","length":368,"tagName":"p"},{"type":"text","content":"The presentation, led by Dr. Amer Zeidan, MBBS, MHS, focused on the preliminary efficacy, safety, and immune biomarker data from 20 first patients with relapsed or refractory high-risk myelodysplastic syndromes (r/r MDS) who had failed prior hypomethylating agent (HMA) therapies. 90% of the patients were very high/high risk at baseline and 50% had tp53 mutations. These patients represent a population with extremely limited treatment options and aggressive and difficult-to-treat disease. The BEXMAB Phase 1 & 2 MDS patients with prior HMA failure experienced an estimated median overall survival (mOS) of approximately 13.4 months, compared to the 5-6 months that would typically be expected under standard of care historically.","length":736,"tagName":"p"},{"type":"text","content":"The BEXMAB study evaluated bexmarilimab (1, 3, or 6 mg/kg ...